The portfolio maintains a sizable cost advantage over competitors, priced within the second-lowest fee quintile among peers.
Loncar Cancer Immunotherapy ETF CNCR
Morningstar’s Analysis CNCR
Will CNCR outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 20.9
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Geron Corp | 3.05 | 552,261 | Healthcare |
ImmunityBio Inc Ordinary Shares | 2.27 | 412,029 | Healthcare |
Cullinan Therapeutics Inc | 2.17 | 393,653 | Healthcare |
Acrivon Therapeutics Inc | 2.12 | 384,522 | Healthcare |
Deciphera Pharmaceuticals Inc | 2.08 | 377,610 | Healthcare |
Enliven Therapeutics Inc | 2.05 | 371,539 | Healthcare |
Janux Therapeutics Inc Ordinary Shares | 2.01 | 365,084 | Healthcare |
Nuvation Bio Inc Ordinary Shares - Class A | 1.91 | 346,128 | Healthcare |
Day One Biopharmaceuticals Inc | 1.63 | 295,370 | Healthcare |
Revolution Medicines Inc Ordinary Shares | 1.59 | 287,656 | Healthcare |